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Abstract: Background Lung volume reduction surgery (LVRS) is a treatment option for selected patients
with severe chronic obstructive pulmonary disease (COPD) and emphysema. The positive effects of LVRS
on exercise capacity are well known. In contrast, the effect of LVRS on daily physical activity (PA) is
less clear. Methods In a prospective case-control study we evaluated selected patients with severe COPD
and emphysema who underwent LVRS and COPD patients following usual care. Controls were matched
for age, severity of airflow obstruction (FEV) and hyperinflation [residual volume to total lung capacity
(RV/TLC)]. Treatment effect of LVRS on activity parameters was analysed using univariable regression
model adjusting for treatment group. Results A total of 19 patients underwent LVRS and 16 COPD
patients without a surgical intervention during the study period were included. The median (quartile)
FEV% was 28% (range, 21-33%), RV/TLC was 69% (range, 64-73%) in cases while controls had a median
(quartile) FEV% of 33% (range, 28.5-49.5%) and a RV/TLC of 58% (range, 49-61%). Age and body
mass index (BMI) were comparable between both groups. Number of steps per day following LVRS was
comparable to before the intervention (mean change: -115, 95% CI: -994.6 to 764.3, P=0.779) and was
not significantly different to the change in control subjects (mean treatment effect: 931.4, 95% CI: -252.4
to 2,115.1, P=0.117). Conclusions The results from this study reveal that patients undergoing LVRS did
not increase their daily level of PA despite improvement of exercise capacity and symptoms.
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Abstract
Reduced physical activity is an important feature of Chronic Obstructive Pulmonary Disease (COPD). Various activity
monitors are available but their validity is poorly established. The aim was to evaluate the validity of six monitors in patients
with COPD. We hypothesized triaxial monitors to be more valid compared to uniaxial monitors. Thirty-nine patients (age
6867years, FEV1 54618%predicted) performed a one-hour standardized activity protocol. Patients wore 6 monitors (Kenz
Lifecorder (Kenz), Actiwatch, RT3, Actigraph GT3X (Actigraph), Dynaport MiniMod (MiniMod), and SenseWear Armband
(SenseWear)) as well as a portable metabolic system (Oxycon Mobile). Validity was evaluated by correlation analysis
between indirect calorimetry (VO2) and the monitor outputs: Metabolic Equivalent of Task [METs] (SenseWear, MiniMod),
activity counts (Actiwatch), vector magnitude units (Actigraph, RT3) and arbitrary units (Kenz) over the whole protocol and
slow versus fast walking. Minute-by-minute correlations were highest for the MiniMod (r = 0.82), Actigraph (r = 0.79),
SenseWear (r = 0.73) and RT3 (r = 0.73). Over the whole protocol, the mean correlations were best for the SenseWear
(r = 0.76), Kenz (r = 0.52), Actigraph (r = 0.49) and MiniMod (r = 0.45). The MiniMod (r = 0.94) and Actigraph (r = 0.88)
performed better in detecting different walking speeds. The Dynaport MiniMod, Actigraph GT3X and SenseWear Armband
(all triaxial monitors) are the most valid monitors during standardized physical activities. The Dynaport MiniMod and
Actigraph GT3X discriminate best between different walking speeds.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a chronic
disease characterized by poorly reversible airflow limitation and
destruction of lung parenchyma. However, COPD is now
recognized as a systemic illness with significant extra-pulmonary
features such as muscle wasting and weakness [1]. Physical
inactivity is known to contribute to these extra-pulmonary features
[2,3]. A recent systematic literature review showed that physical
activity is reduced in patients with COPD [4].
Physical activity is defined as any bodily movement produced by
the contraction of skeletal muscle that increases energy expendi-
ture above a basal level [5]. In the general population, lack of
physical activity is associated with the burden of chronic disease.
Similarly, there is increasing evidence that reduced physical
activity worsens the prognosis of patients with COPD. Hence,
inactivity is not only a manifestation of disease severity in COPD,
but is intrinsic to disease progression [6].
Physical activity monitors are frequently used to estimate levels
of daily physical activity. These devices use piezoelectric acceler-
ometers, which measure the body’s acceleration, in one, two or
three axes (uniaxial, biaxial or triaxial activity monitors). The
signal can then be transformed into an estimate of energy
expenditure using one of a variety of algorithms, or summarized as
activity counts or vector magnitude units (reflecting acceleration).
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With the information obtained in the vertical plane or through
pattern recognition, steps or walking time can also be derived by
some monitors. The availability of sophisticated physical activity
monitors has made the objective measurement of physical activity
in COPD patients possible in a number of contexts, including
assessment of the response to pharmacotherapy [7], during
rehabilitation programmes [8] and during inpatient admission
[9]. Most of the monitors currently available have been validated
in healthy subjects, but not necessarily in patients with chronic
diseases. As such patients are less physically active and move more
slowly than healthy subjects [10,11], the validity of these monitors
to detect movement in these patients needs to be evaluated.
The aim of this study was to validate six physical activity
monitors in COPD patients, against a gold standard of indirect
calorimetry in the form of VO2 data from a portable metabolic
system. Since triaxial accelerometers have previously been
reported to be more effective compared to uniaxial accelerometers
[12], we hypothesized that triaxial activity monitors would be
more valid tools compared to uniaxial activity monitors. The work
described here forms part of the EU/IMI-funded PROactive
project to develop and validate a patient reported outcome for
physical activity in COPD (www.proactivecopd.com).
Materials and Methods
Study Subjects
Ten patients were recruited in each of the 4 centres (Athens,
Edinburgh, Leuven and London) to give a total number of 40
patients. All patients were diagnosed with COPD ranging in
severity from mild to very severe according to the Global Initiative
for Chronic Obstructive Lung Disease (or GOLD) (stages I to IV)
[13]. They were clinically stable and free of exacerbations for at
least 4 weeks prior to the study. Patients were excluded if they had
other co-morbidities which would interfere with their movement
patterns (e.g. arthritis), or if they were on long-term or ambulatory
oxygen therapy, as they could not have supplemental oxygen
whilst wearing the metabolic equipment. The protocol was
approved by the ethics committee of each centre; Medical Ethical
Board of the University Hospitals Leuven (Leuven, Belgium),
NRES Committee London - Bloomsbury (London, United
Kingdom), Sotiria Hospital Scientific and Ethics Commitee
(Athens, Greece) and Lothian Regional Ethics Committee
(Edinburgh, United Kingdom). Patients provided written informed
consent.
Pulmonary Function Testing
All pulmonary function measurements were performed with
standardized equipment and according to American Thoracic
Society and European Respiratory Society guidelines [14]. Post-
bronchodilator spirometry was measured and lung diffusion
capacity was determined by the single breath carbon monoxide
gas transfer method (DLCO). All variables are given as absolute
values and expressed as percentages of the predicted reference
values [15,16].
Six-minute Walking Test
Functional exercise capacity was determined by six minute
walking distance (6MWD) [17]. Values were related to previously
published reference values [18].
Incremental Exercise Testing
A symptom-limited incremental cycle ergometer test according
to the ATS/ACCP statement on cardiopulmonary exercise testing
[19], was used to assess the maximal exercise capacity (peak VO2).
The values of peak oxygen consumption were related to previously
described reference values [20].
COPD-specific Health-related Quality of Life
Questionnaires
The St.-George’s Respiratory Questionnaire (SGRQ) provides
a total score and three component scores for symptoms, activity
and impacts. Each score ranges from 0 (no impairment) to 100
(worst possible) [21].
The COPD Assessment Test (CAT) covers eight items (cough,
phlegm, chest tightness, breathlessness, going up hills/stairs,
activity limitations at home, confidence leaving home, sleep and
energy). Each item is scored from 0 to 5 giving a total score range
from 0 to 40, corresponding to the best and worst health status in
patients with COPD, respectively [22].
The Medical Research Council (MRC) dyspnoea scale rates the
type and magnitude of dyspnoea according to five grades of
increasing severity [23].
Study Design
Each patient wore 6 activity monitors simultaneously which
were selected as a result of a systematic review of the literature.
These were two uniaxial activity monitors [Kenz Lifecorder
(Kenz), Actiwatch (Actiwatch)], three triaxial activity monitors
[RT3, Actigraph GT3X (Actigraph), DynaPort MiniMod (Mini-
Mod)] and one multisensor activity monitor combining a triaxial
accelerometer with different sensors [SenseWear Armband (Sense-
Wear)]. More details about software, type, body location and
outputs of these monitors can be found in Table 1.
Patients also wore a portable metabolic system (Jaeger Oxycon
Mobile), an oxygen saturation finger probe and a Polar T31
(Polar) coded transmitter belt for heart rate monitoring. The
portable metabolic system was attached to the upper chest with a
harness and due to its low weight (950 g), caused minimal
discomfort. A face mask with a dead space of ,30 mL (Hans
Rudolph Inc, Kansas City MO/USA) was used. Location of
attachment for the Oxycon Mobile together with the six activity
monitors is shown in Figure 1. A two-point gas calibration was
completed prior to each test. Oxygen consumption (VO2), carbon
dioxide production (VCO2), heart rate, respiratory rate and tidal
volume were measured continuously. Breath-by-breath measure-
ments were averaged over one-minute intervals. After the
experiment, stored data were downloaded from the portable
metabolic device to a personal computer. VO2 values were divided
by participants’ body weight and converted to Metabolic
Equivalents of Task (METs) [24]. Energy expenditure estimates
from the portable metabolic system (METs) were used as a
criterion measure for energy expenditure and were compared with
the following activity monitor outputs: Kenz - arbitrary units (AU);
Actiwatch - activity counts (AC); Actigraph and RT3 - vector
magnitude units (VMU); MiniMod and SenseWear - METs.
Patients were instructed to perform a strict schedule of activities
lasting 59 minutes (Table 2) which were chosen to be
representative of everyday tasks (such as walking, stair climbing
and sweeping the floor) that are reported as problematic by COPD
patients [25]. Time was kept with both a stopwatch and a laptop
computer clock so that activities were completed in whole minutes.
Statistical Analysis
Minute-by-minute data from all devices were compiled for each
patient in one database and synchronisation was verified by
inspection of the curves to ensure the best fit between the monitors
on a patient-by-patient basis. Analyses were carried out as follows
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(Pearson Product Moment Correlation was used for all correlation
analyses):
1. A minute-by-minute correlation between METs from the
portable metabolic system and each of the activity monitor
outputs was calculated for every patient. Correlations between
minute-by-minute VO2 and activity monitor outputs were
reported as median with interquartile range. A Kruskal-Wallis
test was used to compare results between different activity
monitors. A median correlation larger than 0.7 was defined a
priori as representing evidence of validity.
To investigate whether correlations became weaker with
decreasing six minute walking distance (i.e. slower overall
walking speed), and therefore if a monitor’s performance
worsened as patients moved more slowly, the relationship
between these minute-by-minute correlations and the six-
minute walking distance (6 MWD) was tested. Correlation
coefficients (minute-by-minute) in patients with mild to
moderate COPD (GOLD I/II) were compared to those with
severe to very severe COPD (GOLD III/IV).
2. The mean METs level for the 59 minutes was calculated and
correlated to the mean activity monitor output over this period.
A statistically significant relationship was judged a priori as
indicative of validity.
3. The response of monitors to slow and fast walking was assessed
by evaluating the correlation between changes in METs and
changes in activity monitor outputs at the different speeds. For
this analysis the first minute of each walking phase was
excluded; stronger correlations were taken to indicate greater
validity. A sub-analysis included the response to inclined versus
flat treadmill walking in triaxial compared to uniaxial monitors
(paired t-test). Bland regression analyses [26] were performed
to test the agreement between indirect calorimetry (METs) and
the activity monitor outputs. The 95% prediction limits of the
METs at the mean (of the different activity monitor outputs)
were calculated.
4. To investigate the total variance potentially explained by the
most valid monitor(s), their output information was inserted
into different linear regression models to investigate the total
(R2) and partial variance (pR2) in mean VO2 explained by each
activity monitor.
Statistical analyses were performed with SAS software (version
9.2). A p-value ,0.05 was considered to be statistically significant.
Figure construction was performed with GraphPad Prism Version
4.0.
Results
Patient characteristics are listed in Table 3. One patient was
excluded from the analysis due to a technical problem with the
collection of breath-by-breath data, leaving 39 patients in the final
analysis. Due to technical problems, data collected from the RT3
in one centre could not be used, leaving 29 patients with RT3 in
the final analysis. None of the included patients reported
significant co-morbidities and all had normal exercise electrocar-
diograms.
An example of one patient’s data is provided Figure S1. The
mean VO2 for all activities during the experiment was
8.561.5 ml*min21*kg21 which corresponded to a moderate
intensity of activity (i.e. approximately 50% of VO2peak).
Minute-by-minute correlations between metabolic cost (METs)
and activity monitor output are shown in Figure 2. Strong
correlations (R.0.7 [interquartile range, IQR]) were found with
the MiniMod (0.82 [IQR 0.72 to 0.85]), Actigraph (0.79 [IQR
0.74 to 0.85]), SenseWear (0.73 [IQR 0.63 to 0.81]) and RT3
(0.73 [IQR 0.64 to 0.79]) compared to the Actiwatch (0.53 [IQR
0.41 to 0.62]) and Kenz (0.57 [IQR 0.39 to 0.65]). This difference
was also statistically significant (p,0.05).
These individual minute-by-minute correlations [95% confi-
dence interval (95% CI)] were moderately but significantly related
to the 6MWD for the Actiwatch (r = 0.60 [95% CI 0.35–0.77]),
MiniMod (r = 0.51 [95% CI 0.23–0.71]), SenseWear (r = 0.48
[95% CI 0.19–0.69]) and Actigraph (r = 0.47 [95% CI 0.18–
0.69]). No differences were observed for minute-by-minute
correlations in mild to moderate COPD (GOLD I/II) compared
to severe and very severe COPD (GOLD III/IV) as showed in
Table 4.
The mean correlation between metabolic cost (METs) and
activity monitor outputs over the whole protocol was, from highest
Table 1. Details of type, location and output of the six activity monitors.
Name, Manufacturer (software) Type Location Measured output Estimated output
Kenz Lifecorder Plus Suzuken Co
Ltd., Nagoya, Japan (Physical Activity
Analysis Software)
Uniaxial accelerometer Waist (left) Steps, activity score EE, activity intensity level
Actiwatch, MiniMitterCo,Sunriver,
OR, USA (Respironics Actiware 5)
Uniaxial accelerometer Wrist (left) AC
RT3, Stayhealthy Inc. Monrovia, CA,
USA (Stayhealthy RT3 Assist Version
1.0.7)
Triaxial accelerometer Waist (right) AC, VMU EE
Actigraph GT3X, Actigraph LLC
Pensacola, FL (Actilife 5)
Triaxial accelerometer Waist (right) Steps, AC EE, activity intensity level
DynaPortH MiniMod, McRoberts BV,
The Hague, The Netherlands
Triaxial accelerometer Waist (lower back) Steps, movement Intensity,
different body positions
EE
SenseWear Armband, Bodymedia,
Pittsburgh, PA, USA (SenseWear
Professional 6.0)
Multisensor device: triaxial
accelerometer + sensors (heat
flux, galvanic skin response and
skin temperature)
Upper left arm at triceps Steps, activity intensity level EE
AC; activity counts, VMU: vector magnitude unit, EE; energy expenditure.
doi:10.1371/journal.pone.0039198.t001
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to lowest; SenseWear (r = 0.76 [95% confidence interval (95% CI)
0.54–0.91]), Kenz (r = 0.52 [95% CI 0.27–0.73]), Actigraph
(r = 0.49 [95% CI 0.28–0.64]), MiniMod (r = 0.45 [95% CI
0.21–0.61]), Actiwatch (r = 0.37 [95% CI 0.17–0.56]), all p,0.05
and RT3 (r = 0.35 [95% CI 20.04–0.48], p = 0.06) (Figure 3).
Patients changed their walking speed by 1.31 km/h from the
slow (3.2760.47 km/h) to the fast (4.6561.28 km/h) walking
phase. As expected, the change in walking speed correlated with
the change in VO2 determined by the metabolic equipment
(r = 0.65) and rose from 3.1160.74 METs to 3.9361.23 METs.
All monitors detected this increase in energy expenditure during
fast walking compared to slow walking via their outputs. The
highest correlations were reported for the MiniMod (r = 0.94 [95%
confidence interval (CI) 0.89–0.97]) and Actigraph (r = 0.88 [95%
Figure 1. Location of attachment for the Oxycon Mobile and the six activity monitors.
doi:10.1371/journal.pone.0039198.g001
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CI 0.77–0.93]) compared to the RT3 (r = 0.69 [95% CI 0.42–
0.85]), Actiwatch (r = 0.59 [95% CI 0.34–0.76]), Kenz (r = 0.57
[95% CI 0.31–0.76]) and SenseWear (r = 0.52 [95% CI 0.25–
0.72]), all p,0.0001. As one would expect, walking on an incline
on the treadmill (3.9260.92 METs) expended more energy than
walking on the flat (3.4860.75 METs), as measured by indirect
calorimetry (p,0.0001), but no differences between the two
activities were detected by any of the activity monitors (Figure 4).
Bland regression analyses demonstrated significant relationships
(p,0.05) between METs derived from indirect calorimetry and
the different activity monitor outputs, except for the RT3
(p = 0.06) (Figure 5). The 95% limits of prediction for METs
(derived from indirect calorimetry) at the mean (3.59 METs) were
from lowest to highest: 61.13 METs (SenseWear), 61.15 METs
(Actigraph), 61.17 METs (MiniMod), 61.25 METs (Actiwatch),
61.28 METs (Kenz) and 61.41 METs (RT3).
The Sensewear, Actigraph and MiniMod monitors together
explained 62% of the variance in mean VO2. Partial variances by
different sequences of activity monitors are presented in Table 5.
Most variance in mean VO2 was explained by the SenseWear
(58%) compared to the Actigraph (24%) and the MiniMod (21%).
Little variance in mean VO2 was explained over and above the
SenseWear, when it was introduced into the regression model first.
In fact, introduction of the SenseWear further improved
prediction models from other monitors (range 34 to 41%)
compared to Actigraph (range 0 to 7%) and MiniMod (range 3
to 4%).
Discussion
The validity of six commercially available activity monitors was
investigated by comparing activity monitor outputs for each
monitor to actual VO2 measured with indirect calorimetry.
Triaxial activity monitors were judged to be more valid compared
to uniaxial activity monitors according to a number of pre-defined
criteria. Correlations between minute-by-minute outputs and VO2
were the highest with the Dynaport MiniMod, Actigraph GT3X,
SenseWear Armband and RT3, all exceeding the a priori threshold
of 0.7. Similarly the average monitor output over the 59 minute
assessment was related to the average VO2 with the best
correlations reported for three triaxial activity monitors (Sense-
Wear Armband (r = 0.76), Actigraph GT3X (r = 0.49) and
Dynaport MiniMod (r = 0.45)) and one uniaxial activity monitor
(Kenz Lifecorder (r = 0.52)). All monitors were able to detect
modest changes in walking speed but two triaxial activity monitors
had the strongest correlations (MiniMod (r = 0.94) and SenseWear
(r = 0.88)). Walking on an incline was more intense compared to
flat walking when assessed with indirect calorimetry but no
differences were detected by any of the monitors. All activity
monitor outputs showed similar variability in predicting energy
expenditure. The 95% prediction limits for mean METs
(3.59 METs) varied between 61.13 METs (SenseWear) and
61.41 METs, (RT3). This implies that, from a clinical perspec-
Table 2. Schedule of physical activities in the standardized
protocol.
Activity Duration (minutes)
Standing 1
Lying 3
Sitting 2
Standing 2
Slow walk* 6
Sitting 2
Standing 2
Fast walk* 6
Sitting 2
Standing 2
Sweeping 2
Sitting 2
Standing 2
Lifting 2
Sitting 2
Walking/standing 1
Stairs 1
Sitting 5
Walking/standing 1
Walking on treadmill (flat)** 4
Standing 2
Walking on treadmill (4% incline)** 4
Walking/standing 1
Sitting 2
*These walking activities were performed in a 30 m corridor. Speeds were self-
selected. During fast walking, patients were instructed to walk as fast as
possible.
**Participants walked at 85% of their fast walking speed, first on the flat and
then at an incline of 4%. Participants were instructed not to support their arms
during treadmill walking.
doi:10.1371/journal.pone.0039198.t002
Table 3. Characteristics of the 39 patients.
Variable COPD patients (n =39)
Age (years) 67.967.4
Gender (male/female, n) 25/14
FEV1 (L) 1.4360.60
FEV1 (%predicted) 54618
FVC (L) 2.9760.85
FVC (%predicted) 90616
GOLD stage I/II/III/IV (n) 4/18/14/3
BMI 26.265.2
6 MWD (m) 4386115
6 MWD (%predicted) 70618
VO2peak (ml*min
21*kg21) 16.965.5
VO2peak (%predicted) 79631
MRC 2.660.7
CAT 1568
SGRQ
Total Score 42618
Activities 60624
Impacts 30617
Symptoms 44623
Data are expressed as mean 6 std. FEV1; forced expiratory volume in 1 s, FVC;
forced vital capacity, 6 MWD; six-minute walking distance, MRC; Medical
Research Council, CAT; COPD Assessment Test, SGRQ; St George’s Respiratory
Questionnaire.
doi:10.1371/journal.pone.0039198.t003
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tive, predicting oxygen consumption directly from different activity
monitor outputs is not accurate. However, when patients engage
in activity, monitors are highly capable of detecting the increase in
physical activity levels within a range of 1 to 1.5 METs.
This is the first multi-center trial where several activity monitors
have been validated against VO2 in different stages of COPD.
Until now, only the Dynaport MiniMod and SenseWear Armband
had been validated against VO2 in patients with COPD. In these
devices, similar correlation coefficients were previously reported
between activity monitor outputs and total energy expenditure
(r = 0.75 and r = 0.93 for the SenseWear Armband [27,28], r = 0.7
for the Dynaport Minimod [27]). During a set of 5 daily activities,
a high level of agreement between SenseWear Armband
(22.767 kcal) and indirect calorimetry (21.067.9 kcal) was
observed [29]. In a similar protocol, a fair agreement between
energy expenditure estimate from the SenseWear Armband and
energy expenditure measure from indirect calorimetry was
reported (mean difference of 20.2 METs with a limit of
agreement of 1.3 METs) [30].
In the present study, validity was assessed using correlation
analysis rather than a measure of agreement (e.g. Bland and Altman
analysis), as most of the activity monitor outputs are in different
units (activity counts, vector magnitude units, etc.) to each other,
and to the VO2 data. It is not possible to convert all monitor outputs
to energy expenditure. Several prediction equations are available to
convert some outcomes (e.g. VMU) to energy expenditure and
energy expenditure can also be derived from the VO2 data for direct
comparison. However, whilst the prediction equations used by the
Actigraph (7164 model and GT1M), Actiwatch, Kenz and RT3 are
publicly available, [31,32,33,34], the SenseWear and MiniMod use
proprietary algorithms developed by the device manufacturers.
Moreover, the goal of the study was to assess the validity of the
devices rather than their prediction equations. Therefore, compar-
ing the raw data from the activity monitor with the VO2 (derived
from the portable metabolic kit) by using correlation analysis was
the most appropriate statistical approach.
In addition, energy expenditure is driven to a large extent by a
number of other factors. Whilst specific factors such as body
weight, age, and height can be incorporated into prediction
equations, it is more difficult to include non-specific factors such as
mechanical efficiency, especially in patients with COPD. Patients
with COPD have a larger active energy expenditure [35] even
though it is well recognized that they are moving less. This is
consistent with findings of reduced mechanical efficiency in these
patients compared to healthy controls [36,37]. An activity monitor
cannot be expected to incorporate such a complex change in an
estimate of energy expenditure, so perhaps greater weight should
be placed upon direct monitor outputs (steps, activity counts,
vector magnitude units, etc.). In essence, this means that activity
monitors are most appropriately used for the assessment of the
activities of patients in terms of amount and/or intensity and it
should be acknowledged that the derivation of energy expenditure
is imperfect. Therefore, the use of derived energy expenditure is
also not appropriate when assessing monitor performance.
Figure 2. Minute-by-minute correlations (R) between activity monitor outputs and metabolic equivalents of task (METs) per patient
(white dots). MM; MiniMod, AG; Actigraph, SW; SenseWear, AW; Actiwatch, VMU; vector magnitude unit, AC, activity count, AU; arbitrary unit.
Dotted line corresponds to a correlation of 0.7, defined a priori as supporting monitor validity. Median (interquartile range) correlation for each
activity monitor is reflected by cross bars, *p,0.05.
doi:10.1371/journal.pone.0039198.g002
Table 4. Minute-by-minute correlations between indirect
calorimetry (METs) and activity monitor output in mild to
moderate COPD (GOLD I/II) and severe to very severe COPD
(GOLD III/IV).
Activity monitor output GOLD I/II (n = 22) GOLD III/IV (n =17)
MiniMod (METs) 0.82 [0.81–0.86] 0.77 [0.68–0.83]
SenseWear (METs) 0.78 [0.68–0.83] 0.65 [0.59–0.75]
Actigraph (VMUs) 0.81 [0.74–0.86] 0.77 [0.74–0.83]
ActiWatch (Activity counts) 0.58 [0.46–0.64] 0.45 [0.28–0.53]
RT3 (VMUs) 0.69 [0.34–0.78] 0.76 [0.64–0.79]
Kenz (Arbitrary units) 0.54 [0.42–0.64] 0.59 [0.38–0.65]
Data are expressed as median [interquartile range]. METs; Metabolic Equivalents
of Task, VMUs; Vector Magnitude Units.
doi:10.1371/journal.pone.0039198.t004
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The ability of an activity monitor to pick up a difference in
walking speed of 1.31 km/hr is clinically relevant. Patients with
COPD do walk more slowly than healthy subjects, which is
reflected, for example, by their reduced six minute walking
distance [38,39]. In our study, all monitors were able to detect
these modest changes in walking speed.
A limitation of this study was that inter- and intra-device
reliability of the different activity monitors was not evaluated.
This is important when physical activity levels of patients are
followed over time. Several studies have shown moderate to high
inter-device reliability (intra-class correlation coefficient (rICC)=0.99
for the Actigraph Model 7164 [40], rICC=0.95 for the Kenz
Figure 3. Relation between the activity monitor outputs and indirect calorimetry (METs). Data points represent mean values over the
whole protocol. MM; MiniMod, AG; Actigraph, SW; SenseWear, AW; Actiwatch, VMU; vector magnitude unit, AC; activity count, AU; arbitrary unit.
doi:10.1371/journal.pone.0039198.g003
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Lifecorder [41] and rICC=0.75 for the RT3 [42]) as well as intra-
device reliability (rICC=0.98 for the Actiwatch [43], rICC=0.97 for
the SenseWear Armband [44] and rICC=0.86–0.99 for the Dynaport
Minimod [45]). Besides the concepts of validity and reliability, other
factors like size and scope of the study, usability and cost of the activity
monitor need to be taken into consideration when selecting an
activity monitor for use in clinical trials.
The validation of these activity monitors in a laboratory setting
(validation against VO2) can be considered as an important step in
ascertaining their validity. An essential next step will be to confirm
their validity in a field setting.
In conclusion, this study found that three triaxial activity
monitors (Dynaport MiniMod, Actigraph GT3X and SenseWear
Armband) were the best monitors to assess standardized and
common physical activities in the range of intensity relevant to
Figure 4. METs (derived from indirect calorimetry (IC)) and different activity monitor outputs during flat and inclined walking on a
treadmill (both at the same speed (85% of their fastest walking speed during 6 MWT). MM; MiniMod, SW; SenseWear, AG; Actigraph, AW;
Actiwatch. Symbols represent the mean, error bars the standard error of the mean.
doi:10.1371/journal.pone.0039198.g004
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Figure 5. Bland regression analysis between METs derived from indirect calorimetry (IC) and different activity monitor outputs.
Solid lines represent regression lines, dotted lines represent 95% limits of prediction.
doi:10.1371/journal.pone.0039198.g005
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patients with COPD. Changes in walking speed are most
accurately registered by the Dynaport MiniMod and Actigraph,
which are both devices that are worn on the hip. This should guide
users in choosing valid activity monitors for research or for clinical
use in patients with chronic diseases such as COPD.
Supporting Information
Figure S1 Example of one patient’s experiment; data of
the Oxycon Mobile (VO2 (METs)) and the different
activity monitor outputs.
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